Joaquim Polido-Pereira

Learn More
OBJECTIVES Adalimumab, etanercept and infliximab are effective TNF inhibitors (TNFis) in the treatment of RA, but no randomized clinical trials have compared the three agents. Prior observational data are not consistent. We compared their effectiveness over 1 year in a prospective cohort. METHODS Analyses were performed on subjects' first episode of TNFi(More)
INTRODUCTION Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by sustained synovitis. Recently, several studies have proposed neutrophils and Th17 cells as key players in the onset and perpetuation of this disease. The main goal of this work was to determine whether cytokines driving neutrophil and Th17 activation are(More)
OBJECTIVES To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria. METHODS We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013. We assessed(More)
BACKGROUND The aim of our work was to replicate, in a Southern European population, the association reported in Northern populations between PTPRC locus and response to anti-tumor necrosis factor (anti-TNF) treatment in rheumatoid arthritis (RA). We also looked at associations between five RA risk alleles and treatment response. METHODS We evaluated(More)
BACKGROUND Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents. OBJECTIVES To review the literature and update the(More)
Elsa Vieira-Sousa1,2, João Cavaleiro3, Ana Filipa Mourão4, 5, Ana M. Rodrigues2,5,6 António Albino-Teixeira7, Fernando M Pimentel-Santos4,5, Filipa Oliveira-Ramos1,2, Helena Canhão5, Joaquim Polido Pereira1,2, João Eurico Fonseca1,2, José António Pereira da Silva8, José Carlos Romeu1,2, José Melo Gomes9, Lúcia Costa10, Luís Graça2, Maria José Leandro11,(More)
BACKGROUND The pre-symptomatic stage of Rheumatoid arthritis (RA) is associated with pro-inflammatory cytokines and autoantibodies. High levels and epitope spread by Rheumatoid factors (RhF) and autoantibodies to citrullinated proteins signify progression towards disease expression. In established RA, the persistence of high autoantibody levels reflects(More)
Helena Canhão, Ana Maria Rodrigues, Maria José Santos, Diana Carmona-Fernandes, Bruno F. Bettencourt, Jing Cui, Fabiana L. Rocha, José Canas Silva, Joaquim Polido-Pereira, José Alberto Pereira Silva, José António Costa, Domingos Araujo, Cândida Silva, Helena Santos, Cátia Duarte, Rafael Cáliz, Ileana Filipescu, Fernando Pimentel-Santos, Jaime Branco, Juan(More)
OBJECTIVE B cells play important roles in rheumatoid arthritis (RA). Given the beneficial effect of B cell depletion therapy in RA as well as the observed alterations in B cell subpopulations in this disease, we evaluated whether changes in the expression of genes related to B cell survival and activation were already present in patients with untreated very(More)
Among human peripheral blood (PB) monocyte (Mo) subsets, the classical CD14(++) CD16(-) (cMo) and intermediate CD14(++) CD16(+) (iMo) Mos are known to activate pathogenic Th17 responses, whereas the impact of nonclassical CD14(+) CD16(++) Mo (nMo) on T-cell activation has been largely neglected. The aim of this study was to obtain new mechanistic insights(More)